Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 545-554 , October 2004

Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators

  • Stamos Theocharis

      Affiliations

    • Department of Forensic Medicine and Toxicology, Medical School, University of Athens, 75, Mikras Asias Street, GR 11527 Athens, Greece
    • Unit of Cytology and Cytometry, Department of Tumor Biology, Medical Section, Institut Curie, 26, rue d'Ulm, 75231 Paris Cedex 05, France
    • Corresponding Author InformationCorresponding author. Present address: 21 Thessalias Street, Zografou, Athens 15772, Greece. Tel./fax: +30-210-778-0114
    • ,
  • Alexandra Margeli

      Affiliations

    • Department of Clinical Biochemistry, “Aghia Sophia” Children's Hospital, Thivon and Papadiamandopoulou Street, GR 11527 Athens, Greece
    • ,
  • Philippe Vielh

      Affiliations

    • Unit of Cytology and Cytometry, Department of Tumor Biology, Medical Section, Institut Curie, 26, rue d'Ulm, 75231 Paris Cedex 05, France
    • ,
  • Gregory Kouraklis

      Affiliations

    • Department of Surgery, Medical School, “Laikon” Hospital, University of Athens, 17, Aghiou Thoma Street, GR 11527 Athens, Greece

References 

  1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–650
  2. Peters JM, Vanden Heuvel JP. Peroxisomes, peroxisome proliferators and peroxisome proliferators-activated receptors (PPARs). In:  Vanden Heuvel JP,  Perdew GH,  Mattes WB,  Greenlee WF editor. Comprehensive toxicology. vol. Xiv:Elsevier Science BV; 2002;p. 133–158
  3. Puddu P, Puddu GM, Muscari A. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?. Int. J. Cardol. 2003;90:133–140
  4. Keller JM, Collet P, Bianci A, et al.  Implications of peroxisome proliferator-activated receptors (PPARs) in development, cell life status and disease. Int. J. Dev. Biol. 2000;44:429–442
  5. Wahli W, Braissant O, Desvergne B. Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem. Biol. 1995;2:261–266
  6. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000;43:527–550
  7. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879–887
  8. Kliewer SA, Forman BM, Blumberg B, et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA. 1994;91:7355–7359
  9. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598–5604
  10. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 1992;6:1634–1641
  11. Gottlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA. 1992;89:4653–4657
  12. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA. 1993;90:2160–2164
  13. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 2003;85:267–273
  14. Koeffler PH. Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 2003;9:1–9
  15. Lee C-H, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144:2201–2207
  16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995;270:12953–12956
  17. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem. Biophys. Res. Commun. 1991;175:866–871
  18. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224–1234
  19. Bar-Tana J. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans. Toxicol. Lett. 2001;120:9–19
  20. Green S, Wahli W. Peroxisome proliferator-activated receptors: finding the orphan a home. Mol. Cell. Endocrinol. 1994;100:149–153
  21. Wang M, Tafuri S. Modulation of PPARγ activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J. Cell Biochem. 2003;89:38–47
  22. Huang Q, Alvares K, Chu R, Bradfield CA, Reddy JK. Association of peroxisome proliferator-activated receptor and Hsp 72. J. Biol. Chem. 1994;269:8493–8497
  23. Miyata KS, McCaw SE, Patel HV, Rachubinski RA, Capone JP. The orphan nuclear hormone receptor LXR alpha interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signalling. J. Biol. Chem. 1996;271:9189–9192
  24. Zhu Y, Qi C, Jain S, Rao MS, Reddy JK. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J. Biol. Chem. 1997;272:25500–25506
  25. Zhu Y, Calandra C, Rao MS, Reddy JK. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor-gamma. Gene Expr. 1996;6:185–195
  26. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M. p300 functions as a coactivator for the peroxisome proliferator-activated receptor-alpha. J. Biol. Chem. 1997;272:33435–33443
  27. Misra P, Owuor ED, Li W, et al.  Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). Stimulation of transcriptional regulation by mitogen-activated protein kinase. J. Biol. Chem. 2002;277:48745–48754
  28. Sakai M, Matsushima-Hibiya Y, Nishizawa M, Nishi S. Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between jun and peroxisome proliferator-activated receptor alpha. Cancer Res. 1995;55:5370–5376
  29. Gurnell M. PPARγ and metabolism: insights from the study of human genetic variants. Clin. Endocrinol. 2003;59:267–277
  30. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999;20:649–688
  31. Girnun GD, Spiegelman BM. PPARγ ligands: taking part in chemoprevention. Gastroenterology. 2003;124:564–567
  32. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992;11:433–439
  33. Camp HS, Li O, Wise SC, et al.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes. 2000;49:539–547
  34. Maeda N, Takahashi M, Funahashi T, et al.  PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–2099
  35. Combs TP, Wagner JA, Berger J, et al.  Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143:998–1007
  36. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARγ-dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001;7:48–52
  37. Chinetti G, Lestavel S, Bocher V, et al.  PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 2001;7:53–58
  38. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 2000;60:5494–5549
  39. Segawa Y, Yoshimura R, Hase T, et al.  Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate. 2002;51:108–116
  40. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J. Biol. Chem. 2001;276:29681–29687
  41. Satoh T, Toyoda M, Hoshino H, et al.  Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene. 2002;21:2171–2180
  42. Downes CP, Bennett D, McConnachie G, et al.  Antagonism of PI 3-kinase-dependent signaling pathways by the tumour suppressor protein, PTEN. Biochem. Soc. Trans. 2001;29:846–851
  43. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol. 2001;11:764–768
  44. Jang MK, Choi MS, Park YB. Regulation of ferritin light chain gene expression by oxidized low density lipoproteins in human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 1999;265:577–583
  45. Stephens JM, Morrison RF, Wu Z, Farmer SR. PPARgamma ligand-dependent induction of STAT1, STAT5A, and STAT5B during adipogenesis. Biochem. Biophys. Res. Commun. 1999;262:216–222
  46. Fajas L, Debril M-B, Auwerx J. Peroxisome proliferator-activated receptor gamma: from adipogenesis to carcinogenesis. J. Mol. Endocrinol. 2001;27:1–9
  47. Fajas L, Landsberg RL, Huss-Garcia Y, Sardet C, Lees JA, Auwerx J. E2Fs regulate adipocyte differentiation. Dev. Cell. 2002;3:39–49
  48. Altiok S, Xu M, Spiegelman BM. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997;11:1987–1998
  49. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferators-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 S transition in vascular smooth muscle cells. J. Biol. Chem. 2000;275:22435–22441
  50. deDios ST, Bruemmer D, Dilley D, et al.  Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation. 2003;107:2548–2550
  51. Bruemmer D, Berger JP, Liu J, et al.  A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur. J. Pharmacol. 2003;466:225–234
  52. Morrison RF, Farmer SR. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18 (INK4c) and p21 (Waf1/Cip1), during adipogenesis. J. Biol. Chem. 1999;274:17088–17097
  53. Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas. 2002;24:1–7
  54. Eibl G, Wente MN, Reber HA, Hines OJ. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem. Biophys. Res. Commun. 2001;287:522–529
  55. Itami A, Watanabe G, Shimada Y, et al.  Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int. J. Cancer. 2001;94:370–376
  56. Koga H, Sakisaka S, Harada M, et al.  Involvement of p21(WAF1/Cip1), p27 (Kip1), and p18 (INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001;33:1087–1097
  57. Shao J, Sheng H, Dubois RN. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 2002;62:3282–3288
  58. Michalik L, Desvergne B, Tan NS, et al.  Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J. Cell Biol. 2001;154:799–814
  59. Westergaard M, Henningsen J, Svendsen ML, et al.  Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 2001;116:702–712
  60. Hupfeld CJ, Weiss RH. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am. J. Physiol. Endocrinol. Metab. 2001;281:E207–E216
  61. Yin F, Wakino S, Liu Z, et al.  Troglitazone inhibits growth of MCF-7 breast carcinoma cell by targeting G1 cell cycle regulators. Biochem. Biophys. Res. Commun. 2001;286:916–922
  62. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999;1:330–339
  63. Asou H, Verbeek W, Williamson E, et al.  Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int. J. Oncol. 1999;15:1027–1031
  64. Hirase N, Yanase T, Mu Y, et al.  Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology. 1999;57(Suppl 2):17–26
  65. Fujimura S, Suzumiya J, Nakamura K, Ono J. Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int. J. Oncol. 1998;13:1263–1267
  66. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999;455:135–139
  67. Konopleva M, Andreeff M. Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. Curr. Opin. Hematol. 2002;9:294–302
  68. Haydon RC, Zhou L, Feng T, et al.  Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin. Cancer Res. 2002;8:1288–1294
  69. Panigrahy D, Shen LQ, Kieran MW, Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Invest. Drugs. 2003;12:1925–1937
  70. Debril M-B, Renaud J-P, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferators-activated receptor γ. J. Mol. Med. 2001;79:30–47
  71. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 2002;277:22320–22329
  72. Rohn TT, Wong SM, Cotman CW, Cribbs DH. 15-Deoxy-delta12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis. Neuroreport. 2001;12:839–843
  73. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut. 2002;50:658–664
  74. Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001;22:1379–1383
  75. Toyoda M, Takagi H, Horiguchi N, et al.  A ligand for peroxisome proliferator-activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut. 2002;50:563–567
  76. Tsubouchi Y, Sano H, Kawahito Y, et al.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem. Biophys. Res. Commun. 2002;270:400–405
  77. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin. Cancer Res. 2002;8:1206–1212
  78. Kouraklis G, Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr. Med. Chem. Anti-Canc Agents. 2002;2:477–484
  79. Elstner E, Muller C, et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA. 1998;95:8806–8811
  80. Clay CE, Namen AM, Atsumi G, et al.  Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999;20:1905
  81. Clay CE, Atsumi GI, High KP, Chilton FH. Early de novo gene expression is required for 15-deoxy-Delta 12,14-prostaglandin J2-induced apoptosis in breast cancer cells. J. Biol. Chem. 2001;276:47131–47135
  82. Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP. 15-deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. J. Lipid Res. 2002;43:1818–1828
  83. Kato M, Nagaya T, Fujieda M, Saito K, Yoshida J, Seo H. Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines. Jpn. J. Cancer Res. 2002;93:660–666
  84. Chattopadhyay N, Singh DP. Heese O, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J. Neurosci. Res. 2000;61:67–74
  85. Han S, Wada RK, Sidell N. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res. 2001;61:3998–4002
  86. Zander T, Kraus JA, Grommes C, et al.  Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J. Neurochem. 2002;81:1052–1060
  87. Nishida K, Furumatsu T, Takada I, et al.  Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor- gamma. Br. J. Cancer. 2002;86:1303–1309

PII: S0305-7372(04)00079-9

doi: 10.1016/j.ctrv.2004.04.004

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 545-554 , October 2004

Article Tools

* Image Usage & Resolution